SecBot SecBot
6-K ·Filed Sep 1, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001654954-26-007983
Notable filing: 6-K
Actionable Insight ▲ Bullish

The SANOVO data de-risk the Tagrisso+Orpathys first-line regulatory path in China and strengthen the overall Tagrisso franchise against emerging EGFR-TKI competition. Traders should watch for regulatory submission timelines in China and potential global filings; the SAFFRON global readout in the post-Tagrisso setting further supports the combination's broad utility. Near-term catalyst is data presentation at a medical meeting.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

AZN drug pipeline →

ORPATHYS

◆ Mixed Named in this 6-K
Impact
Phase
Approved in China (3 indications); global Phase 3 readout pending
Time to market
Already approved and marketed in China (lung cancer since 2021, gastric cancer July 2026). Ex-China (US/EU) approval is not filed yet — timing hinges on the SAFFRON global Phase 3 readout expected H2 2026.
Next catalyst
None dated

What to watchWatch for SAFFRON/SANOVO Phase 3 topline data in H2 2026, a positive readout supports global (ex-China) filings for savolitinib and would be the biggest near-term share-price lever; a miss or delay would hit a stock already near its 52-week low ($11.13 vs $18.30 high). HUTCHMED carries $1.37B cash, so the stock isn't a financing story, but this one drug's readout is the dominant H2 catalyst alongside sovleplenib NDA decisions.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20
Entry
$162.47
T+0 close · Sep 1, 2026 · via day close
Latest settled
+0.47%
T+20 · $163.23 · next T+60 in 8d
Vs SPY
−0.71%
α at T+20
Latest observation
+14.90%
T+52 · FF3 residual α
  1. T+0 · Sep 1 $162.47entry
  2. T+1 · 3mo ago −0.52%α −0.96% · $161.63
  3. T+5 · 2mo ago −3.40%α −3.49% · $156.94
  4. T+20 · 7w ago +0.47%α −0.71% · $163.23
  5. T+53 · todayOpen
  6. T+60 · in 8d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca announced positive Phase III SANOVO trial results showing Tagrisso plus Orpathys achieved a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) versus Tagrisso alone in first-line MET-overexpressing EGFR-mutated NSCLC. The combination also showed encouraging overall survival benefit. These data extend the all-oral combination into the first-line setting, reinforcing Tagrisso's backbone role and supporting regulatory submissions in China.

Key Facts

  • SANOVO Phase III trial met primary endpoint: statistically significant and highly clinically meaningful PFS improvement for Tagrisso + Orpathys vs Tagrisso alone in 1L EGFRm MET-overexpressing NSCLC.
  • PFS benefit demonstrated in both high MET (IHC 3+) and ITT (IHC 2+, IHC 3+) populations.
  • Overall survival, a secondary endpoint, showed very encouraging clinical benefit; trial continuing follow-up.
  • Safety profile consistent with known profiles of each medicine; no new safety findings.
  • Data will be presented at a forthcoming medical meeting and shared with regulatory authorities.
  • Combination already approved in China for post-EGFR-TKI MET-amplified patients (SACHI trial) and recently reported positive SAFFRON global Phase III results in post-Tagrisso setting.
  • Orpathys is jointly developed by AstraZeneca and HUTCHMED, commercialized by AstraZeneca.

Financial Impact

Positive Phase III data in 1L EGFRm NSCLC with MET overexpression expands addressable patient population for Tagrisso + Orpathys combination; Tagrisso is a multi-billion-dollar franchise and this label extension supports revenue durability against competitive pressure.

revenuepipeline value

Risk Factors

  • Regulatory approval in China is not guaranteed; SANOVO is a China-only trial and may require additional global data for ex-China filings.
  • Competitive landscape includes other EGFR-MET bispecific antibodies and combination approaches that could limit market share.
  • Overall survival data are still immature; final OS readout could alter the risk/benefit profile.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (35 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-007983
Document: 0001654954-26-007983-index-headers.html0001654954-26-007983
Document: 0001654954-26-007983-index.html0001654954-26-007983
Document: 0001654954-26-007983.txt0001654954-26-007983

Track record

77 reports on AZN

Performance horizon

19 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.45 −0.59% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.45 −0.46% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.45 −0.35% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.45 −1.28% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.45 −1.18% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.45 +8.45% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.45 +6.88% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (11h 56m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 1, 2026